Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33581821

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2021 Feb 13
First author
Sezer A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Feb 13;397(10274):557-559. doi: 10.1016/S0140-6736(21)00196-3.
    note
    Source null
    related pmid
    33581807
    relationship
    Comment in

Authors and identifiers

  1. name
    Sezer A
    type
    Author
  2. name
    Kilickap S
    type
    Author
  3. name
    Gümüş M
    type
    Author
  4. name
    Bondarenko I
    type
    Author
  5. name
    Özgüroğlu M
    type
    Author
  6. name
    Gogishvili M
    type
    Author
  7. name
    Turk HM
    type
    Author
  8. name
    Cicin I
    type
    Author
  9. name
    Bentsion D
    type
    Author
  10. name
    Gladkov O
    type
    Author
  11. name
    Clingan P
    type
    Author
  12. name
    Sriuranpong V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Sezer A
    type
    Author
  2. name
    Kilickap S
    type
    Author
  3. name
    Gümüş M
    type
    Author
  4. name
    Bondarenko I
    type
    Author
  5. name
    Özgüroğlu M
    type
    Author
  6. name
    Gogishvili M
    type
    Author
  7. name
    Turk HM
    type
    Author
  8. name
    Cicin I
    type
    Author
  9. name
    Bentsion D
    type
    Author
  10. name
    Gladkov O
    type
    Author
  11. name
    Clingan P
    type
    Author
  12. name
    Sriuranpong V
    type
    Author
bibliography ids
  1. nci-bib-33f88955ea16305cbdc5e64e
book metadata
content sha256
d3ff1bb285e0cfbe382631ffea77d771e949f59ad6e4399df593f408c4c71187
document type
citation
dois
  1. 10.1016/S0140-6736(21)00228-2
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:33581821
immutable id
pubmed:33581821@d3ff1bb285e0cfbe382631ffea77d771e949f59ad6e4399df593f408c4c71187
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10274
name
Lancet (London, England)
nlm unique id
2985213R
pages
592-604
volume
397
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Feb 13;397(10274):557-559. doi: 10.1016/S0140-6736(21)00196-3.
    note
    Source null
    related pmid
    33581807
    relationship
    Comment in
outcomes validated
false
pmid
33581821
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
2d8346f979f834e0c62ed462beff524bcadddbbbcaa89f5f73da70d89d595a02
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Feb 13
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33581821/
title
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

Preserved source evidence · Not medical advice